2016-03-30

Guogen Shan, PhD, Assistant Professor of Biostatistics, Department of Environmental and Occupational Health, School of the Community Health Sciences, University of Nevada, Las Vegas

"Adaptive designs for phase II cancer clinical trials"

Phase II cancer clinical trial designs currently in use are generally not flexible and effective enough to increase the success rate of clinical trial studies. Unlike traditional single-arm two-stage designs, adaptive designs allow the study to change along with the information observed. Only a very few adaptive designs have been developed for phase II cancer clinical trials with binary endpoints, and the majority of them cannot be directly applied in clinical trials because of the counter-intuitive feature of these designs with regard to the relationship between sample size and the number of responses. We will use an integer algorithm to develop a new adaptive single-arm optimal design. In addition to new adaptive design development, we also propose developing proper statistical inference for clinical trials that do not follow the design precisely. The proposed novel adaptive design has the potential to increase the success rate of cancer clinical trials, and benefit cancer patients.

Stay connected TwitterFacebookLinkedInYouTubeInstagram